ClinVar Miner

Submissions for variant NM_000179.2(MSH6):c.1474A>G (p.Met492Val) (rs61754783)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000587662 SCV000149283 uncertain significance not provided 2018-10-18 criteria provided, single submitter clinical testing This variant is denoted MSH6 c.1474A>G at the cDNA level, p.Met492Val (M492V) at the protein level, and results in the change of a Methionine to a Valine (ATG>GTG). Although this variant was observed in three individuals with colorectal cancer from families suspicious for Lynch syndrome, as well as at least one individual with ovarian cancer (Wagner 2003, Nilbert 2009, Okkels 2012, Pal 2012), in vitro analysis demonstrated mismatch repair activity comparable to wild-type (Drost 2012). This variant has also been reported in individuals with pancreatic neuroendocrine tumor, breast cancer, or thyroid cancer (Shindo 2017, Lovejoy 2018, Yehia 2018). The International Society for Gastrointestinal Hereditary Tumours Incorporated (InSiGHT) classifies MSH6 Met492Val as a variant of uncertain significance due to insufficient evidence for classification (Thompson 2014). MSH6 Met492Val was observed at an allele frequency of 0.04% (11/25,786) in individuals of Finnish ancestry in large population cohorts (Lek 2016). This variant is located within the mismatch binding domain (Warren 2007, Kansikas 2011). In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, it is unclear whether MSH6 Met492Val is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Ambry Genetics RCV000115374 SCV000185429 uncertain significance Hereditary cancer-predisposing syndrome 2018-04-04 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence,Rare (0.1%) in general population databases (dbsnp, esp, 1000 genomes) ,In silico models in agreement (deleterious) and/or completely conserved position in appropriate species
Invitae RCV000524111 SCV000260884 uncertain significance Hereditary nonpolyposis colon cancer 2018-12-03 criteria provided, single submitter clinical testing This sequence change replaces methionine with valine at codon 492 of the MSH6 protein (p.Met492Val). The methionine residue is highly conserved and there is a small physicochemical difference between methionine and valine. This variant is present in population databases (rs61754783, ExAC 0.05%). This variant has been reported in individuals from families with suspected Lynch syndrome (PMID: 12658575, 22495361, 18566915), in an individual affected with ovarian cancer (PMID: 23047549) and an individual with pancreatic cancer (PMID: 28767289). ClinVar contains an entry for this variant (Variation ID: 89195). Experimental studies have shown that this missense change does not affect MSH6 mismatch repair activity in an in vitro assay (PMID: 22102614). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000212649 SCV000592585 uncertain significance not specified 2014-07-21 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000587662 SCV000695784 uncertain significance not provided 2016-08-24 criteria provided, single submitter clinical testing Variant summary: The MSH6 c.1474A>G (p.Met492Val) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 7/121326 control chromosomes at a frequency of 0.0000577, which does not exceed the estimated maximal expected allele frequency of a pathogenic MSH6 variant (0.0001421). The variant has been reported in the literature in patients/families with suspected Lynch Syndrome (Nilbert_2009, Okkels_2012, Wagner_2003) and ovarian cancer (Pal_2012), without strong evidence for causality (lacking co-segregation data). Despite its presence in affected individuals, an in vitro assay showed the variant to have similar MMR activity compared to WT (Drost_2011). Multiple clinical diagnostic laboratories/reputable databases classified this variant as uncertain significance. Taken together, this variant is classified as VUS until additional evidence becomes available.
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000212649 SCV000712331 uncertain significance not specified 2016-11-30 criteria provided, single submitter clinical testing The p.Met492Val variant in MSH6 has been reported in 4 individuals with Lynch sy ndrome-related cancers (Wagner 2003, Okkels 2012, Pal 2012). In vitro functional studies provide some evidence that the p.Met492Val variant may not impact prote in function (Drost 2012). However, these types of assays may not accurately repr esent biological function. This variant has been identified in 3/6610 Finnish ch romosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute. org; dbSNP rs61754783). Computational prediction tools and conservation analysis do not provide strong support for or against an impact to the protein. In addit ion, this variant was classified as a Variant of Uncertain Significance on Sep 5 , 2013 by the ClinGen-approved InSiGHT expert panel (ClinVar SCV000107859.2). In summary, the clinical significance of the p.Met492Val variant is uncertain.
PreventionGenetics,PreventionGenetics RCV000587662 SCV000805844 uncertain significance not provided 2017-05-15 criteria provided, single submitter clinical testing
Color RCV000115374 SCV000902794 likely benign Hereditary cancer-predisposing syndrome 2016-03-10 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.